The Food and Drug Administration turned down a bid from Neuralink, the ambitious yet controversial human brain chip startup founded by Elon Musk to begin human trials.
The agency urged Neuralink to address a variety of issues before beginning human trials – like the potential of the device’s tiny wires to move to other parts of the human brain, and concerns surrounding the safe removal of the device from the brain.
The rejection happened about a year ago, and the company is currently working through these issues. Neuralink is now almost certain to miss its target date for FDA approval of March 7, 2023, which was predicted by Elon Musk last year.
